Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Arcus ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Arcus Biosciences in a report issued on ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer ...

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago. These ...

Investors in Arcus Biosciences Inc (Symbol: RCUS) saw new options become available this week, for the October 17th expiration. One of the key data points that goes into the price an option buyer ...

Universal Health Realty Income Trust announced today that for the three-month period ended December 31, 2024, net income was $4.7 million, or $.34 per diluted share, as compared to $3.6 million, or $.